Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Grottoli

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Journal of Endocrinological Investigation|March 9, 2010
Primary empty sella: Why and when to investigate hypothalamic-pituitary functionA Giustina, G Aimaretti, M Bondanelli, et al.
Clinical Endocrinology|June 9, 2007
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyC L Ronchi, M Boschetti, E C Degli Uberti, et al.
Journal of Endocrinological Investigation|June 23, 2009
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyG Lombardi, F Minuto, G Tamburrano, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|May 12, 2004
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI)G Aimaretti, M R Ambrosio, S Benvenga, et al.
Journal of Endocrinological Investigation|October 30, 2017
How to improve effectiveness of pegvisomant treatment in acromegalic patientsM Ragonese, S Grottoli, P Maffei, et al.
Journal of Endocrinological Investigation|October 15, 2008
Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patientsR Attanasio, A Mainolfi, F Grimaldi, et al.
Journal of Endocrinological Investigation|October 10, 2007
Pegvisomant in acromegaly: why, when, howA Colao, G Arnaldi, P Beck-Peccoz, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Journal of Endocrinological Investigation|March 9, 2010
Primary empty sella: Why and when to investigate hypothalamic-pituitary functionA Giustina, G Aimaretti, M Bondanelli, et al.
Clinical Endocrinology|June 9, 2007
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyC L Ronchi, M Boschetti, E C Degli Uberti, et al.
Journal of Endocrinological Investigation|June 23, 2009
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyG Lombardi, F Minuto, G Tamburrano, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|May 12, 2004
Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI)G Aimaretti, M R Ambrosio, S Benvenga, et al.
Journal of Endocrinological Investigation|October 30, 2017
How to improve effectiveness of pegvisomant treatment in acromegalic patientsM Ragonese, S Grottoli, P Maffei, et al.
Journal of Endocrinological Investigation|October 15, 2008
Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patientsR Attanasio, A Mainolfi, F Grimaldi, et al.
Journal of Endocrinological Investigation|October 10, 2007
Pegvisomant in acromegaly: why, when, howA Colao, G Arnaldi, P Beck-Peccoz, et al.
Pageof 13